Tianxin Pharmaceutical Reports 48.24% Gross Margin on Vitamin B Series in H1 2024, a Year-on-Year 8.37% Increase
Continue reading with Effamall membership.
Already a member? Login here.
Tag:
Copy Link
<Prev
Next>
<Prev
Next>
